Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amphastar Pharmaceuticals (AMPH) Operating Leases (2019 - 2025)

Historic Operating Leases for Amphastar Pharmaceuticals (AMPH) over the last 7 years, with Q3 2025 value amounting to $39.4 million.

  • Amphastar Pharmaceuticals' Operating Leases rose 3628.07% to $39.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $39.4 million, marking a year-over-year increase of 3628.07%. This contributed to the annual value of $41.9 million for FY2024, which is 4091.38% up from last year.
  • Amphastar Pharmaceuticals' Operating Leases amounted to $39.4 million in Q3 2025, which was up 3628.07% from $39.0 million recorded in Q2 2025.
  • Amphastar Pharmaceuticals' 5-year Operating Leases high stood at $41.9 million for Q4 2024, and its period low was $16.5 million during Q1 2021.
  • Over the past 5 years, Amphastar Pharmaceuticals' median Operating Leases value was $25.5 million (recorded in 2022), while the average stood at $28.7 million.
  • In the last 5 years, Amphastar Pharmaceuticals' Operating Leases soared by 6899.52% in 2021 and then plummeted by 586.53% in 2023.
  • Over the past 5 years, Amphastar Pharmaceuticals' Operating Leases (Quarter) stood at $24.7 million in 2021, then decreased by 4.08% to $23.7 million in 2022, then grew by 25.44% to $29.7 million in 2023, then soared by 40.91% to $41.9 million in 2024, then dropped by 5.83% to $39.4 million in 2025.
  • Its last three reported values are $39.4 million in Q3 2025, $39.0 million for Q2 2025, and $40.7 million during Q1 2025.